Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer

NCT03780075 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: 1.11GBq of 177Lu-EB-PSMA-617
DRUG: 2.00 GBq of 177Lu-EB-PSMA-617
DRUG: 3.70GBq of 177Lu-EB-PSMA-617

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]